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Behavioral symptomsAlthough several studies have pointed to a possible role of interleukin 2 (IL-2) in schizophrenia (SZ), association
between IL-2 and the different groups of symptoms has not been explored. The objective of this study was to in-
vestigate a possible correlation of peripheral IL-2 levels with symptoms and cognitive performance in patients
with SZ. In addition, we compared the plasma levels of IL-2 between patients with SZ and healthy controls.
Twenty-nine chronically medicated outpatients with SZ according to DSM-IV were compared with twenty-six
healthy controls. The patients were evaluated with the Positive and Negative Syndrome Scale (PANSS), the
Calgary Depression Scale for Schizophrenia (CDSS), the Clinical Global Impression (CGI) and the Global Assess-
ment of Functioning (GAF). All the participants had blood collected into EDTA tubes by venipuncture between
9:00 and 10:00 AM. Plasma concentrations of IL-2 were determined by cytometric bead array. A computerized
neuropsychological battery assessed verbal learning, verbal ﬂuency, working memory, set shifting, execu-
tive function, inhibition and intelligence. Patients with SZ had lower levels of IL-2 than healthy controls
(p b 0.001). In the SZ group, IL-2 levels were positively correlated with scores in the digit span test (rho =
0.416, P = 0.025) and intelligence (rho = 0.464, P = 0.011). We also found a negative correlation between
IL-2 and total score in the negative subscale of PANSS (rho =−0.447, p = 0.015). Our ﬁndings suggest that
IL-2 may be involved in the mechanisms related to cognitive deterioration and negative symptomatology in
schizophrenia.
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Schizophrenia (SZ) is a chronic, severe and highly prevalent mental
disorder that is frequently associated with signiﬁcant disability [1].
Symptoms of SZ are often divided into two clusters: positive symptoms
(hallucinations, delusions, disorganized speech and behavior) and neg-
ative symptoms (blunted affect, social withdrawal, loss of volition and
alogia) [1]. In addition to thepositive andnegative syndromes, cognitive
impairment is an essential feature of SZ that seems to be directly associ-
ated with functional disability in work, poor social functioning and
difﬁculties in daily life activities [2,3]. When compared with healthy in-
dividuals, people diagnosed with SZ display deﬁcits in several domains
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hibition, language and executive functions [4]. Notwithstanding recent
advances, causes underlying SZ as well as its different symptomatic
manifestations remain largely unknown. Considering the lack of reliable
biomarkers, diagnosis, assessment and prognosis of SZ are based on
symptomatology alone, which hinders the implementation of personal-
ized treatments [5].
In the last decade, immunological alterations in individuals affected
bymajor mental disorders, such as SZ, have received great attention, as
they can aid to further elucidate related pathophysiological pathways
[6–9]. One of the most promising approaches to evaluate immune
changes in SZ is the measurement of cytokines in serum or plasma
[10]. Cytokines are molecular mediators of the immune system. They
are involved in a complex and redundant network that communicates
immune and non immune cells [11].
Interleukin 2 (IL-2) is a cytokine of 15.5kd discovered more than
30 years ago. First described as a T cell growth factor, IL-2 is mainly
produced by T cells after interaction of MHC/antigen/T-cell receptor
(TCR) and co-stimulatory molecules. IL-2 acts as an autocrine and para-
crine third signal, inducing clonal expansion and effector T and B-cells
development. It also plays an important role on innate immunity, lead-
ing to activation and proliferation of natural killer (NK) cells [12]. Sever-
al studies have pointed to a potential role of IL-2 in SZ,withmost studies
reporting altered peripheral levels of IL-2 when comparedwith healthy
controls [13,14], as well as a reduction in production of IL-2 by leuko-
cytes after mitogen stimulation [15–18]. Nevertheless, association be-
tween IL-2 and different groups of symptoms of SZ, namely positive,
negative and cognitive, has not been explored.
The objective of this study was to investigate a possible correlation
of peripheral IL-2 levels with symptomatology and cognitive perfor-
mance of patients with SZ. In addition, we compared serum levels of
this cytokine between patients with SZ and healthy controls. We hy-
pothesized that individuals with SZ would exhibit decreased levels of
IL-2 when compared to healthy controls. Moreover, we expected to
demonstrate that decreased levels of IL-2 are associated with worse
psychopathological features and lower cognitive performance.
2. Material and methods
The study protocol was approved by the Ethics Committee of the
Universidade Federal de São Paulo (UNIFESP), in São Paulo, Brazil, and
all individuals provided their written informed consent before inclusion
in the study. This study is part of a large protocol entitled “Prevention of
Schizophrenia and Bipolar Disorder from Neuroscience to Community:
a Multistaging, Multimodal and Translational Platform to Investigation
and Intervention” developed by the Department of Psychiatry of
Universidade Federal de São Paulo (UNIFESP). The sample investigated
here had already been evaluated regarding other biomarkers and out-
comes [8,19].
2.1. Study population
Twenty-nine chronically medicated outpatients were compared
with twenty-six healthy controls. The diagnosis of SZ was established
according to the Diagnostic and Statistical Manual of Mental Disorders,
fourth Edition (DSM-IV), using the Structured Clinical Interview for
DSM-IV (SCID). The patients were also evaluated with the Positive and
Negative Syndrome Scale (PANSS) for severity of psychotic symptoms,
the Calgary Depression Scale for Schizophrenia (CDSS) for severity of
depressive symptoms, the Clinical Global Impression (CGI) and the
Global Assessment of Functioning (GAF) scales for functioning assess-
ment. All patients were under treatment with atypical antipsychotics
with stable doses for at least 6 weeks prior to the inclusion. Patients
were using Olanzapine (n = 13), Clozapine (n = 10), Risperidone/
Paliperidone (n = 4) and Quetiapine (n = 2). The healthy volunteers
group was matched for age, ethnicity and educational level and hadno current or lifetime psychiatric history according SCID, as well as no
ﬁrst-degree relative with history of psychiatric disorders.
Acute and chronic general medical conditions traditionally associat-
ed with a signiﬁcant inﬂammatory response such as ﬂu-like syndrome,
HIV infection, allergies, pregnancy or postpartumperiod, rheumatologic
or immunological conditions were considered exclusion criteria for
both groups. Individuals using medications with immunomodulatory
effects, such as non-steroidal anti-inﬂammatory drugs, corticosteroids
and immunosuppressants, were also excluded.
2.2. Collection of blood samples and procedures to biomarker measurement
All the participants had blood collected into EDTA tubes by veni-
puncture between 9:00 and 10:00 AM. The samples were immediately
processed and plasma stored at−80 °C. Plasma concentrations of IL-2
were evaluated using a BD cytometric bead array (BD Biosciences, USA).
2.3. Neuropsychological assessment
A computerized neuropsychological battery assessed the following
domains of cognition (for a detailed description of the tests, see previ-
ous publication [20]):
2.3.1. Verbal learning: the Hopkins Verbal Learning Test [21];
2.3.2. Verbal ﬂuency: phonemic and semantic verbal ﬂuency;
2.3.3. Working memory: Visual Working Memory [22,23], Keep
Track Task [24], Letter Memory Task [25] and the forward digit span of
the Wechsler Adult Intelligence Scale [26];
2.3.4. Set shifting (Plus–minus task [27], Number–letter task [28]);
2.3.5. Executive function: Tower of London [29] and Shortened ver-
sion of the Wisconsin Card Sorting Test [30]);
2.3.6. Inhibition: Computerized Stroop Task [31], Semantic Genera-
tion Task [32,33]).
2.3.7. Intelligence: the non-verbal intelligence task (R-1)was used to
assess intelligence. This scale allows measures of intelligence in low lit-
eracy populations, such as Brazilian schizophrenics. This test highly
correlates with the Raven's Colored Progressive Matrices Test (r= 0.76,
p= 0.001) [34].
2.4. Statistical analysis
Statistical analyses were performed using SPSS 20.0 for Mac. All the
distributions of quantitative data were tested for normality using the
Kolmogorov–Smirnov test. Comparisons of clinical and demographic
variables between SZ group and healthy volunteers group were per-
formed using X2, Student t-test andMann–WhitneyU-testwhen appro-
priate. Differences in IL-2 levels between the two groupswere evaluated
using the Mann–Whitney U-test. Correlation between cognitive tests
and biomarker levels was tested using the Spearman correlation coefﬁ-
cient. Statistical signiﬁcance was set in alpha ≤0.05.
3. Results
Clinical and demographic characteristics of the sample are described
in Table 1. Comparison of levels of IL-2 demonstrated that patients
with SZ had lower levels of this mediator (median = 0.98 pg/mL;
mean (M) = 0.699 pg/mL; standard error of the mean (SE) = 0.105)
than healthy control (HC) individuals (median = 1.31 pg/mL; M =
1.146 pg/mL; SE = 0.120) (Mann–Whitney test U= 177.5, P b 0.001).
In order to clarify a possible inﬂuence of the difference in marital
status on IL-2 levels, we compared IL-2 levels between married (M =
1.084 pg/mL; SE = 0.157) and non-married (M= 1.110 pg/mL; SE =
0.220) controls and found no signiﬁcant differences (Mann–Whitney
test U= 62, P= 0.602). In addition, we compared IL-2 levels between
male (M= 1.212 pg/mL; SE = 0.180) and female (M= 1.089 pg/mL;
SE = 0.166) controls and also found no signiﬁcant differences (Mann–
Whitney test U = 75, P = 0.667). The low number of married and
Table 1
Clinical and demographic characteristics of the sample.
SZ group N = 29 HC group N = 26 Test-value P-value
Age in years (mean, SD) 33.17 (9.73) 34.65 (10.64) 0.537* 0.594
Sex (% female) 17.2% 53.8% 8.124** 0.004
Years of education (mean, SD) 10.50 (2.86) 10.10 (3.88) 0.428* 0.671
Ethnic group (%)
Caucasian 69.0% 47.6%
Afro-American 3.4% 14.3% 3.134** 0.371
Asian 6.9% 9.5%
Other 20.7% 28.6%
Marital status (%)
Single 93.1% 42.86%
Married 0% 57.1% 23.075** b0.001
Other 6.9% 9.5%
Smoke habit (%)
Never smoke 46.4%% 42.9%
Smoke in the past, not currently 7.1% 9.5% 0.121** 0.941
Currently smoker 46.4% 47.6%
Years of disease (mean, SD) 11.83 (8.43) – – –
PANSS (mean, SD) – – –
PANSS positive scale 13.97 (4.35) – – –
PANSS negative scale 17.14 (5.35) – – –
PANSS general psychopathology 30.28 (7.39) – – –
Total PANSS 61.38 (14.29)
CDSS (mean, SD) 3.83 (4.22) – – –
GAF (mean, SD) 49.26 (13.51) – – –
CGI (mean, SD) 3.96 (0.99) – – –
PANSS: Positive and Negative Symptoms Syndromes Scale; CDSS: Calgary Depression Scale Schizophrenia; GAF: Global Assessment of Functioning; CGI: Clinical Global Impression.
*Student t test.
**X2 test.
196 E. Asevedo et al. / Physiology & Behavior 129 (2014) 194–198female individuals prevented the possibility of performing this analysis
in the SZ group.
Individuals with SZ exhibited deﬁcits in verbal learning (Hopkins
test), when comparedwith healthy subjects. We did not observe differ-
ences in other functions such as inhibitory control, working memory,
planning, verbal ﬂuency and attention, although differences in verbal
ﬂuency were marginally signiﬁcant.
With respect to performance in the neuropsychological assessment,
peripheral IL-2 levels were positively correlated with scores in the digit
span test in the SZ group (rho= 0.416, P= 0.025).We have also found
a positive correlation of IL-2 levels with non-verbal intelligence (rho=
0.464, P = 0.011) in this group. We did not ﬁnd correlations between
IL-2 and cognitive performance in the healthy control group.
We also found a negative correlation between IL-2 and total score in
the negative subscale of PANSS (rho=−0.447, p= 0.015). Speciﬁcally,
the items of blunted affect (rho =−0.445, p = 0.016), poor rapport
(rho =−0.411, p= 0.027) and difﬁculty in abstract thinking (rho =
−0.493, p = 0.007) had statistically signiﬁcant negative correlations
with IL-2. We did not observe correlations with the total PANSS score,
the scores in PANSS subscales, depressive symptoms and global severity
measured by CGI and GAF.
To assess a possible impact of use of different medications in the
included variables, we compared clinical (PANSS total, subscales, CGI
and GAF), cognitive variables (digit span, non-verbal intelligence) and
IL-2 levels between patients using clozapine and other atypical anti-
psychotics and found no signiﬁcant differences in any of the analyses
(Mann–Whitney test, all P N 0.138). Clozapine is the ﬁrst choice for re-
fractory schizophrenia and is the only drugwith evidence of superior ef-
ﬁcacy when compared to other antipsychotics.
4. Discussion
In the presentwork, we explored, for the ﬁrst time, the role of IL-2 in
several clinical parameters of disease severity in individualswith SZ.We
reported that a group of chronically treated SZ individuals had lower
plasma levels of IL-2 as compared to HC. In addition, peripheral IL-2
levels were correlated with clinical and cognitive parameters. Individ-
uals with SZ included in this sample were outpatients in a relativelystable condition. This could explain why we did not ﬁnd signiﬁcant
deﬁcits in most cognitive functions assessed, except verbal learning
(Hopkins test), when compared with healthy subjects. Differences in
verbal ﬂuency were marginally signiﬁcant.
Alterations on the IL-2 system have been detected in SZ. Most stud-
ies observed lower concentrations of IL-2 in patients when compared
with HC, although some studies reported no alterations [6,35–37]. In-
triguingly, in vitro studies have shown that leukocytes from individuals
with SZ when stimulated produce lower levels of IL-2 in comparison to
leukocytes from HC [14,38–40]. Our work contributes to the hypothesis
of diminished IL-2 levels in SZ. Genetic studies demonstrated that the
T allele of−330G/T polymorphism in the IL-2 gene is associated with
an increased risk of developing SZ [41,42]. Functionally, the TT and GT
genotypes of this gene have been linked to a reduced in vitro production
of this cytokine [43], providing a possible explanation for the ﬁndings of
diminished IL-2 levels in SZ. Antipsychotics use could also inﬂuence
these results. Some studies have shown that this class of medications
can affect IL-2 levels, although the results are mostly inconsistent.
Quetiapine, risperidone, clozapine and haloperidol have been linked to
decreased IL-2 production [40,44]. Contrastingly, other studies pointed
to no effect for risperidone, quetiapine and clozapine [45,46] or even
an increase with clozapine and chlorpromazine [44].
Interestingly, there was a negative correlation between IL-2 levels
and the total score in the negative subscale of PANSS. The statistically
signiﬁcant negative correlations of items of blunted affect, poor rapport
and difﬁculty in abstract thinking with IL-2 indicate that perhaps low
levels of this mediator can be speciﬁcally associated with negative psy-
chotic symptoms. These ﬁndings are in line with those of Bresee and
Rapaport [47], reporting a positive association between soluble IL-2 re-
ceptor (sIL-2R) and PANSS total scores, negative and general psychopa-
thology subscales, but not the positive subscale. In opposition to IL-2,
sIL-2R is increased in individuals with schizophrenia when compared
to healthy controls [6].
Regarding neuropsychological assessment, peripheral IL-2 levels
were associated with higher performance in tasks of working memory
and non-verbal intelligence in the SZ group. IL-2 has been reported to
play a role in neuronal proliferation, survival and neuroprotection.
Sarder, Saito [48] reported an IL-2 induced increase in neurite branching
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protective effects, Awatsuji, Furukawa [49] showed that IL-2 promoted
cell survival in cortical, striatal and septal neurons. IL-2 effects are
mediated by binding to its speciﬁc receptor (IL-2R). IL-2 receptor is
expressed in cerebral areas related to cognition, like the neocortex, cer-
ebellum and hippocampus [50]. We have shown that, in our group of
patients, higher IL-2 levels were associated with better cognitive scores,
suggesting that IL-2may be acting as a neuroprotector in SZ individuals.
The results of this studymust be interpreted at light of its limitations.
First, the relatively small sample size limited the possibility to include
more covariates, such as time of illness or current medications. Also,
the results could have been inﬂuenced by the intergroup differences re-
gardingmarital status and sex, although we found no differences in the
levels of IL-2 between married and non-married controls and between
male and female controls. In addition, the cross sectional design does
not allow strong inferences of causality between IL-2 levels and cogni-
tive deﬁcits and symptoms. As all the patients were under antipsychotic
pharmacological treatment, we cannot completely rule out its inﬂuence
on biomarker's levels, which has been previously shown as a potential
confounder. On the other hand, we tried to minimize confounders ex-
cluding individuals with recent changes in medication regimen and
general medical comorbidity. Furthermore, we assessed the possible
impact of clozapine use in IL-2 levels, clinical and cognitive variables
and found no signiﬁcant differences between patients using clozapine
and those using other atypical antipsychotics.
5. Conclusions
Nevertheless, this study indicates that IL-2 could have a relevant role
in the pathophysiology of SZ, being correlated to negative symptoms
and cognitive impairment. Although individuals with SZ had lower
levels of IL-2 when compared to HC, within the SZ group, higher levels
of IL-2 were indicative of less negative symptomatology and a better
cognitive performance. Even though we cannot establish a causal rela-
tionship, this association poses IL-2 as a possible marker of cognitive
and affective preservation in SZ. Considering the complexity of immune
responses, additional studies are necessary to further understand the
underlyingmolecularmechanisms of negative and cognitive symptoms
in SZ and the relationship of the described IL-2 ﬁndings with other rel-
evant inﬂammatory markers.
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